SCHEMBL30129469

SCHEMBL30129469

[N-]=[N+]=Nc1c(S(=O)(=O)F)c(=O)oc2ccccc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.37
▸ KDM4E B2RXH2 5/20 0.37
▸ GAA P10253 2/20 0.37
▸ CYP2C9 P11712 2/20 0.36
▸ CYP3A4 P08684 3/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ MAPT P10636 3/20 0.35
▸ HPGD P15428 2/20 0.35
▸ CASP7 P55210 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ GLA P06280 1/20 0.35
▸ PGAM1 P18669 1/20 0.35
▸ MAOA P21397 1/20 0.35
▸ CASP1 P29466 1/20 0.35
▸ KMT2A Q03164 5/20 0.35
▸ MEN1 O00255 4/20 0.35
▸ NPC1 O15118 2/20 0.34
▸ VKORC1 Q9BQB6 1/20 0.34
▸ MAPK1 P28482 2/20 0.34
▸ NQO1 P15559 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16863152 0.77 KDM4E (0.53) ALDH1A1KDM4EGAACYP2C9CYP3A4
SCHEMBL15542047 0.77 KDM4E (0.49) ALDH1A1KDM4EGAACYP2C9CYP3A4
SCHEMBL15541690 0.74 KDM4E (0.53) ALDH1A1KDM4ECYP2C9CYP3A4SMN1; SMN2
SCHEMBL29950209 0.74 KDM4E (0.53) ALDH1A1KDM4ECYP2C9CYP3A4SMN1; SMN2
SCHEMBL27503546 0.66 SMN1; SMN2 (0.39) ALDH1A1KDM4ECYP2C9SMN1; SMN2MAPT
SCHEMBL29076941 0.66 KMT2A (0.55) ALDH1A1KDM4EGAACYP2C9CYP3A4
SCHEMBL14417276 0.64 NQO1 (0.51) ALDH1A1KDM4ECYP2C9CYP3A4SMN1; SMN2
SCHEMBL304367 0.63 KMT2A (0.62) ALDH1A1KDM4EGAACYP2C9CYP3A4
SCHEMBL29709713 0.63 KMT2A (0.62) ALDH1A1KDM4EGAACYP2C9CYP3A4
SCHEMBL29416517 0.63 KMT2A (0.62) ALDH1A1KDM4EGAACYP2C9CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240293443-A1 HEPARAN SULFATE MIMETICS TO IMPROVE GLUCOSE CLEARANCE GORDTS PHILIP L S M (US) 2024-09-05 — — US claimed
WO-2022261480-A1 HEPARAN SULFATE MIMETICS TO IMPROVE GLUCOSE CLEARANCE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-12-15 — — WO claimed
US-20240293443-A1 HEPARAN SULFATE MIMETICS TO IMPROVE GLUCOSE CLEARANCE GORDTS PHILIP L S M (US) 2024-09-05 — — US disclosed
WO-2022261480-A1 HEPARAN SULFATE MIMETICS TO IMPROVE GLUCOSE CLEARANCE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-12-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240293443-A1 HEPARAN SULFATE MIMETICS TO IMPROVE GLUCOSE CLEARANCE FABP4, APMAP, SLC2A4 ALDH1A1 3423/4885KDM4E 3334/4885GAA 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback